As this is down from $49 million in the prior-year quarter, it’s no wonder investors have been concerned. However, new orders largely disappointed, with this figure coming in at $21 million. VRAY announced that it expects quarterly sales of $17 million, landing very close to the consensus estimate. The share price decline comes on the heels of its preliminary Q4 results. With this groundbreaking offering, why have shares dipped 25% year-to-date? Its approach uses MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. ViewRay is focused on giving clinicians new and more effective ways to treat cancer using radiation.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |